美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · GH近 30 天 18 則 · 第 1 / 1 頁
- Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role
- Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
- Guardant Health Nears Buy Point As Sales Outlook Brightens
- Dow Jones Futures Rise As Oil Prices, Yields Fall Before Fed Rate Hike; Will Market Rally Bid Bond Voyage?
- Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says
- Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
- Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
- Business Insider Names Guardant Health One of America's Most Innovative Businesses
- Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks
- What Makes Guardant Health (GH) a Compelling Bet?
- Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
- Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
- Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
- Guardant Health (GH) Stock Could Trade At A 21% Discount Despite Patent Appeal
- Did a US$245 Million Patent Ruling Just Shift Guardant Health's (GH) Investment Narrative?
- Has Guardant Health (GH) Run Too Far After Its US$245 Million Patent Ruling?
- Guardant Health ordered to pay $245M in patent dispute
- VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
- Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 Outlook
- Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。